11 results about "Cyclosporin a" patented technology

Compositions are disclosed that include acridinium esters of cyclosporin A or C. Kits containing same, as well as methods of making and using same, are also disclosed.

The present disclosure relates to oral compositions of Compound I or its derivatives. Several dosage ranges are disclosed, along with SAD, MAD, and PK data. Comparative data between Compound I, tofacitinib, ritrecitinib, and cyclosporin A are also disclosed. Methods of use for treating inflammatory conditions are also disclosed.

The present application belongs to the field of cell biology, specifically by adding recombinant human DFF45 protein, Z-VAD-FMK, Cyclosporin A, bFGF, N-Acetylcysteine, regulating the activity and effect of apoptosis-specific nuclease, reducing the apoptosis rate of umbilical cord mesenchymal stem cells, and also can improve the proliferation effect of umbilical cord mesenchymal stem cells, the proliferation rate of umbilical cord mesenchymal stem cells is increased by 17.53%, and the apoptosis rate of umbilical cord mesenchymal stem cells by ordinary conventional culture method is reduced from 14.32% to 9.81%, effectively solving the core problem of stem cell proliferation attenuation, apoptosis rate increase in the existing culture technology, maintaining the biological activity and quality stability of stem cells in the long-term subculture process, providing reliable technical support and experimental basis for the large-scale culture, in vitro expansion and subsequent clinical transformation application of umbilical cord mesenchymal stem cells.

The invention discloses a composition. The composition is a combination of any two or three of cyclosporine A, allipovir, allipovir and [MeIle] 4-cyclosporine. The invention also discloses the cyclosporin A, the allipovir, the allipovir, the [MeIle] 4-cyclosporin and the application of the composition in preparation of a preparation for inhibiting proliferation of the African swine fever virus. The medicine has an application prospect.

The present application relates to a cyclosporine A detection reagent and its preparation and detection method, specifically relates to a cyclosporine A chemiluminescence immunoassay reagent and its preparation and detection method, comprising: anti-cyclosporine A specific antibody, indicating reagent for detecting anti-cyclosporine A specific antibody-cyclosporine A combination;The above-mentioned anti-cyclosporine A specific antibody is obtained by immunizing animals with cyclosporine A immunogen.The present application has the advantages that: the cyclosporine A immunogen of the present application is specific and has high immunogenicity, and the prepared anti-cyclosporine A specific antibody is specific and has high titer;The chemiluminescence immunoassay reagent containing the above-mentioned anti-cyclosporine A specific antibody can conveniently, quickly and accurately determine the content of cyclosporine A in the sample, and multiple samples can be simultaneously determined on a fully automatic chemiluminescence immunoassay analyzer, realizing high-throughput rapid determination of cyclosporine A, high accuracy, strong specificity, and great improvement in accuracy and detection efficiency.

To satisfy a need for a technology capable of achieving improved solubility even when the amount of surfactant used is reduced or minimized compared to existing technologies.SOLUTION: Provided is a dispersion composition comprising: a dispersion medium; and particles comprising a target substance, wherein the dispersion composition comprises at least one type of surfactant having a threshold micelle concentration or more, the dispersion composition does not comprise a solubilizer, and the target substance is cyclosporin A, satisfying the S-parameter>1 defined above.SELECTED DRAWING: None

The invention provides a nano antibody for detecting cyclosporine A and application of the nano antibody, and belongs to the technical field of medical detection. The nano antibody comprises complementarity determining regions CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is as shown in SEQ ID NO: 1; the amino acid sequence of the CDR2 is as shown in SEQ ID NO: 2; the amino acid sequence of the CDR3 is as shown in SEQ ID NO: 3. When the nano antibody is used for detecting cyclosporin A, the precision is high, the sensitivity is high, the specificity is good, and the detection result is accurate and reliable.

The present invention is directed to methods for treating diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), wet age-related macular degeneration (AMD) and / or retinal vein occlusion (RVO) in a patient or subject in need comprising administering an effective amount of at least one anti-DME agent selected from the group consisting of desipramine, protriptyline, cyclosporin A, crisaborole, empagliflozin, nitroxolone, suprofen, sulfisoxazole, methapyrilene, phentolamine, naphazoline or a pharmaceutically acceptable salt thereof, preferably at least one agent selected from the group consisting of desipramine, nitroxolone, methapyriline, phentolamine, napthazoline and their pharmaceutically acceptable salts.

The present application relates to a cyclosporine A detection kit. Specifically, the 6-phosphogluconate dehydrogenase mutant of the present application comprises one mutation or a combination thereof selected from the following: D306C, D375C, G426C, compared to wild-type 6-phosphogluconate dehydrogenase. The detection kit prepared using the 6-phosphogluconate dehydrogenase mutant of the present application has strong specificity, high sensitivity, convenient operation, short detection time, accurate quantification, and is suitable for high-throughput detection.

A lipid nano drug delivery system targeting a brain lesion and a preparation method and application thereof. The drug delivery system comprises a lipid, a delivery drug, and a functional penetrating peptide, and the functional penetrating peptide is formed by covalently connecting a peptide chain linking a nanocarrier end, an arginine-rich penetrating peptide, a matrix metalloproteinase-9 sensitive peptide, and a polyanion inhibitory peptide. The lipid nano drug delivery system can be used for targeting the brain lesion and realizing mitochondrial enrichment by means of modification of the functional penetrating peptide. The repair of mitochondria is realized by encapsulating peptide drug cyclosporin A by means of a lipid nanoparticle core by utilizing a dilution-induced precipitation technique, thereby solving the problems that current cyclosporin A is difficult to effectively reach a brain lesion and the therapeutic window is small, and improving the ability to repair cells around the brain lesion with a small administration dose.

The invention relates to the technical field of biological medicine, in particular to a biomarker for evaluating the drug resistance of LGLL combined PRCA patients to cyclosporin A and application of the biomarker. Wherein the TCR comprises a TCR beta chain variable region; the TCR [beta] chain variable region comprises CDR3; and the CDR3 comprises a TRBV06 gene. The sensitivity of the LGLL and PRCA combined patient to CsA treatment is evaluated in advance through detection of the biomarker, selection of treatment schemes of the LGLL and PRCA combined patient is facilitated, and the treatment effect of the LGLL and PRCA combined patient and the prognosis of the LGLL and PRCA combined patient are improved.